264 related articles for article (PubMed ID: 8398922)
1. Antisense of oligonucleotides and the inhibition of oncogene expression.
Prins J; de Vries EG; Mulder NH
Clin Oncol (R Coll Radiol); 1993; 5(4):245-52. PubMed ID: 8398922
[TBL] [Abstract][Full Text] [Related]
2. Rational design of sequence-specific oncogene inhibitors based on antisense and antigene oligonucleotides.
Hélène C
Eur J Cancer; 1991; 27(11):1466-71. PubMed ID: 1835863
[TBL] [Abstract][Full Text] [Related]
3. Antisense strategy: biological utility and prospects in the treatment of hematological malignancies.
Warzocha K; Wotowiec D
Leuk Lymphoma; 1997 Jan; 24(3-4):267-81. PubMed ID: 9156656
[TBL] [Abstract][Full Text] [Related]
4. Antisense therapeutics in chronic myeloid leukaemia: the promise, the progress and the problems.
Clark RE
Leukemia; 2000 Mar; 14(3):347-55. PubMed ID: 10720125
[TBL] [Abstract][Full Text] [Related]
5. Treatment of Philadelphia leukemia in severe combined immunodeficient mice by combination of cyclophosphamide and bcr/abl antisense oligodeoxynucleotides.
Skorski T; Nieborowska-Skorska M; Wlodarski P; Perrotti D; Hoser G; Kawiak J; Majewski M; Christensen L; Iozzo RV; Calabretta B
J Natl Cancer Inst; 1997 Jan; 89(2):124-33. PubMed ID: 8998181
[TBL] [Abstract][Full Text] [Related]
6. Antisense BCR-ABL oligonucleotides induce apoptosis in the Philadelphia chromosome-positive cell line BV173.
Smetsers TF; Skorski T; van de Locht LT; Wessels HM; Pennings AH; de Witte T; Calabretta B; Mensink EJ
Leukemia; 1994 Jan; 8(1):129-40. PubMed ID: 8289478
[TBL] [Abstract][Full Text] [Related]
7. Oligonucleotide therapeutics: clothing the emperor.
Gewirtz AM
Curr Opin Mol Ther; 1999 Jun; 1(3):297-306. PubMed ID: 11713794
[TBL] [Abstract][Full Text] [Related]
8. Effects of BCR-ABL antisense oligonucleotides (AS-ODN) on human chronic myeloid leukemic cells: AS-ODN as effective purging agents.
Wu AG; Joshi SS; Chan WC; Iversen PL; Jackson JD; Kessinger A; Pirruccello SJ; Sanger WG; Sharp JG; Verbik DJ
Leuk Lymphoma; 1995 Dec; 20(1-2):67-76. PubMed ID: 8750625
[TBL] [Abstract][Full Text] [Related]
9. Antisense inhibition of P210 bcr-abl in chronic myeloid leukemia.
Vaerman JL; Lewalle P; Martiat P
Stem Cells; 1993 Oct; 11 Suppl 3():89-95. PubMed ID: 8298481
[TBL] [Abstract][Full Text] [Related]
10. Antisense oligonucleotides: the state of the art.
Aboul-Fadl T
Curr Med Chem; 2005; 12(19):2193-214. PubMed ID: 16178780
[TBL] [Abstract][Full Text] [Related]
11. Phosphorothioate BCR-ABL antisense oligonucleotides induce cell death, but fail to reduce cellular bcr-abl protein levels.
Smetsers TF; van de Locht LT; Pennings AH; Wessels HM; de Witte TM; Mensink EJ
Leukemia; 1995 Jan; 9(1):118-30. PubMed ID: 7845006
[TBL] [Abstract][Full Text] [Related]
12. Ribonuclease H-mediated antisense effects in intact human leukaemia cells.
Tidd DM
Biochem Soc Trans; 1996 Aug; 24(3):619-23. PubMed ID: 8878815
[No Abstract] [Full Text] [Related]
13. Meeting report: antisense oligonucleotides.
Martinelli G; Ferrari S
Haematologica; 1994; 79(2):184-8. PubMed ID: 8063271
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of P210 expression in chronic myeloid leukaemia: oligonucleotides and/or transduced antisense sequences.
Lewalle P; Martiat P
Leuk Lymphoma; 1993; 11 Suppl 1():139-43. PubMed ID: 8251887
[TBL] [Abstract][Full Text] [Related]
15. Antisense oligonucleotides directed against p53 have antiproliferative effects unrelated to effects on p53 expression.
Barton CM; Lemoine NR
Br J Cancer; 1995 Mar; 71(3):429-37. PubMed ID: 7880719
[TBL] [Abstract][Full Text] [Related]
16. BCR-ABL: an anti-apoptosis gene in chronic myelogenous leukemia.
Cotter TG
Leuk Lymphoma; 1995 Jul; 18(3-4):231-6. PubMed ID: 8535187
[TBL] [Abstract][Full Text] [Related]
17. Applications of antisense oligonucleotides in oncology.
Pierga JY; Magdelenat H
Cell Mol Biol (Noisy-le-grand); 1994 May; 40(3):237-61. PubMed ID: 7920172
[TBL] [Abstract][Full Text] [Related]
18. Morpholino Oligo Antisense efficiently suppresses BCR/ABL and cell proliferation in CML: specific inhibition of BCR-ABL gene expression by Morpholino Oligo Antisense in BCR-ABL(+) cells.
Haririan M; Kaviani S; Soleimani M; Ghaemi SR; Delalat B; Atashi A
Hematology; 2012 Jan; 17(1):28-34. PubMed ID: 22549445
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of chronic myelogenous leukemia cells harboring a BCR-ABL B3A2 junction by antisense oligonucleotides targeted at the B2A2 junction.
Mahon FX; Ripoche J; Pigeonnier V; Jazwiec B; Pigneux A; Moreau JF; Reiffers J
Exp Hematol; 1995 Dec; 23(14):1606-11. PubMed ID: 8542954
[TBL] [Abstract][Full Text] [Related]
20. [Autologous bone marrow transplantation for patients with chronic myelogenous leukemia after in vitro purging of the graft with bcr/abl antisense oligodeoxynucleotides].
Sun J; Wu B; Liu Q; Feng R; Liu X; Meng F; Zhou S
Zhonghua Xue Ye Xue Za Zhi; 2000 Aug; 21(8):400-2. PubMed ID: 11877009
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
